Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Novartis Keeps 'JULIET' Study Results Close as Investors and Rival Kite Pharma Wait
Novartis Keeps 'JULIET' Study Results Close as Investors and Rival Kite Pharma Wait
Novartis Keeps 'JULIET' Study Results Close as Investors and Rival Kite Pharma Wait
Submitted by
admin
on April 7, 2017 - 9:45am
Source:
TheStreet.com
News Tags:
Novartis
Kite Pharma
CTL019
diffuse large B-cell lymphoma
Headline:
Novartis Keeps 'JULIET' Study Results Close as Investors and Rival Kite Pharma Wait
Do Not Allow Advertisers to Use My Personal information
